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The past couple of years have seen an unprecedented
number of failures of clinical trials investigating combi-
natorial strategies with immuno-oncology drugs (IODs).
Beyond the highly publicized crashes of the MYSTIC
study1 (anti–PD-L1 plus anti-CTLA4 in non–small-cell
lung cancer [NSCLC]) or the ECHO-301 trial2 (anti–PD-1
and anti-IDO in melanoma), many other attempts to
combine immunotherapy with radiation therapy
(RT),3 chemotherapy,4 metronomic chemotherapy,5
or antiangiogenics6 have similarly led to disap-
pointing results. Because successful immunother-
apy is restricted today to a limited number of patients
in a limited number of cancers (melanoma, lung
cancer, head and neck cancer, and kidney cancer,
with 5-year survival rates , 40%), developing ap-
propriate strategies to stretch efficacy remains critical
(eg, by turning “cold” tumors [noninflammatory with
lack of infiltrating T cells] into “hot” ones [infiltrated by
T cells]). Consequently, combining IODs with other
treatments likely to harness tumor immunity is ap-
pealing. Several studies successfully associated con-
ventional treatments with IODs in comparative phase III
trials.7,8 However, these trials should not hide the high
attrition rate of too many other studies. One of the
common characteristics of the trials is the lack of
computational pharmacology support, plus the lack of
prior knowledge regarding the pharmacokinetics (PK)/
pharmacodynamics (PD) relationships of the combined
treatments. In this respect, it is not a surprise that so
many studies fail today. Actually, the real surprise
comes from the fact that, sometimes, some combina-
torial clinical trials manage to be successful.
To improve the design of such combinatorial trials
beyond trial-and-error methods, we propose an in-
novative strategy termed mechanistic learning (Fig 1).
We define it as the combination of mechanistic
modeling—simulation of the kinetics of pathophysio-
logic processes—and statistical (machine) learning.
Using data generated from previous clinical trials and
preclinical experiments, it consists in building com-
putational models able to simulate and predict the
toxicity and efficacy outcomes of candidate regimens.
The optimal scheduling is then selected for clinical trial
testing. Importantly, the trial data are then recursively
injected in the mechanistic learning process, allowing
to further refine predictions. This learning loop allows
one to understand which of the biologic premises of
the model should be refined or rejected and helps in
the next iteration. In analogy to numerical optimization
algorithms used in scientific computing (eg, gradient
descent), the next trial is thus guided by a rational step,
instead of brute-force exploration of alternatives.
THE CURSE OF DIMENSIONALITY: TOO MANY
COMBINATIONS TO BE TESTED?
Combinatorial studies may lead to suboptimal results
because of the limited number of arms they explore
with respect to the near-infinite number of possi-
ble combinations. Limited options when performing
combinatorial trials are therefore a major caveat,
possibly explaining many failures, or at least limiting
the conclusions regarding the real intrinsic potential of
a given combination. For instance, in the CheckMate-
032 study, the anti–PD-1 nivolumab and the anti-
CTLA4 ipilimumab were administered to patients
with NSCLC using only 2 dosing modes (ie, 1 and
3 mg/kg and vice versa). These doses were chosen
because they were already combined in a previous
phase I study.9 In dose-finding trials, up to 5 dose
levels ranging from 0.1 to 20 mg/kg have been tested
for nivolumab and ipilimumab used as single agents
without reaching dose-limiting toxicities.10,11 Conse-
quently, at least 25 different combinations in dosing
could have been explored in CheckMate-032, not to
mention the countless variations in sequencing and
scheduling. However, without modeling support, only
2 combinatorial arms were tested, thus limiting the
chances to find the optimal dose combination. In the
subsequent CheckMate-143 study, the same strategy
failed to improve survival in patients with glioblastoma.12
Another example of a poorly designed study is the
MODUL umbrella trial, which tested a triple combination
of fluoropyrimidines, the antiangiogenic bevacizumab,
and the anti–PD-L1 atezolizumab in patients with
metastatic colorectal cancer (mCRC). In theory, a
minimum of 12 different sequences should have
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Surprisingly, in this study, all drugs were administered
concomitantly at fixed dosing. This combination failed to
exhibit significant efficacy in terms of progression-free
survival, and thus, the conclusion was that adding atezo-
lizumab to standard of care for maintenance in mCRC
showed no benefit.13 Actually, this conclusion may sound
peremptory because it is not possible to knowwhether or not
different dosing or scheduling with exactly the same drugs
would have performed better. For instance, the combination
of the CDK4/6 inhibitor abemaciclib and anti–PD-L1 showed
that only slight changes in sequencing (ie, 7-day shift) led to
striking differences in antitumor efficacy in mouse models.14
Similar critical impact of timing has been demonstrated
when combining anti–PD-1 and anti–OX-4015 or when
combining RT and IODs.16 Sequences could have a major,
yet largely underestimated influence on efficacy and
should therefore be carefully defined when setting up
combinatorial clinical trials with IODs, especially because
the immunomodulating properties of cytotoxics are both
drug and dose dependent.17
ARE PK/PD RELATIONSHIPS REALLY FLAT WITH IMMUNE
CHECKPOINT INHIBITORS?
Although the tumor-mediated drug disposition phenome-
non can blur the picture when trying to understand the
relationships between drug levels, clearance values, and
tumor shrinkage with IODs, exposure-effect relationships
have already been evidenced with the anti-CTLA4 ipili-
mumab, anti–PD-1 nivolumab, and anti–PD-L1 avelumab,
to name a few.18-20 In this respect, the fact that almost
all exploratory trials testing combinatorial strategies lack
pharmacokinetics support to evaluate the variability
in exposure levels among patients is another major
weakness.21,22 Before concluding that a combination is
ineffective, checking that exposure level with IODs was
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FIG 1. Mechanistic learning. Mechanistic models are mathematical constructs able to simulate pathophysiologic processes. To do so, they depend on
mathematical parameters that need to be calibrated from data. Data available in clinical settings are typically of 3 types. Baseline data can be composed of
demographic, clinical, pathologic (eg, histologic type), molecular (eg, genetic mutations), or biologic (eg, blood counts) variables. Such covariates can be
used as inputs in machine learning algorithms to predict individual values of the parameters. Longitudinal data can include quantities such as tumor size
measurements, pharmacokinetics, immune monitoring, seric biomarkers, or circulating DNA. Mixed-effects statistical learning is well adapted to integrate
these. Survival data (eg, progression-free or overall survival) can also be modeled with a mechanistic basis (instead of biologically agnostic survival analysis
based on, eg, Cox regression), using adapted, survival learning statistical methods. In turn, this allows simulating and optimizing safety and efficacy profiles
of candidate therapeutic regimens for combinatorial trials. CT1, first chemotherapy; CT2, second chemotherapy; mTKI, maintenance tyrosine kinase
inhibitor; PS, performance status; TGI, tumor growth inhibition; TKI, tyrosine kinase inhibitor.
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of possible confounding factors. Importantly, several flaws
can be found even in single-agent studies, blurring the
picture when trying next to decipher PK/PD relationships
with IODs. For instance, in a pivotal phase I trial of
nivolumab,23 the impact of dosing (ie, 0.1-10 mg/kg) on
PD-1 receptor occupancy was investigated. Similar target
engagement (ie, 64%-70%) was achieved regardless of the
dosing, thus prompting several observers to conclude that
PK/PD relationships were flat with IODs and, therefore, that
interpatient variability was not an issue. However, in this
seminal study, PD-1 inhibition was measured only on
circulating T lymphocytes extracted from peripheral blood
and not on infiltrated T lymphocytes in the tumor micro-
environment. Importantly, the pharmacokinetics of most
therapeutic monoclonal antibodies is characterized by
large interindividual variability and reduced ability to diffuse
out of the vascular space and reach solid tumors.24
Therefore, to what extent differences in nivolumab dos-
ing could affect or not target engagement at the tumor
levels, and not only in circulating T cells, remains to be fully
investigated. The once alleged flatness of PK/PD re-
lationships with IODs should therefore not be considered as
granted, as suggested by recent pilot studies showing that
efficacy in patients with NSCLC is correlated with trough
levels of nivolumab and that those are highly variable
among patients.20
PHARMACOMETRICS IN IMMUNO-ONCOLOGY TO DEFINE
DOSING REGIMEN
Shifting from speculative to model-informed designs is
an appealing strategy to reduce the attrition rates during
clinical development phases in oncology, where drug
candidates still exhibit a . 90% risk of failure when en-
tering in phase I.25 PK/PD modeling is regularly presented
as a possible means to improve development of new en-
tities, especially when determining first-in-human doses
and recommended phase II doses.26 With pembrolizumab,
the initial approved dosing was based on such analysis that
determined the sufficient dose to ensure meaningful target
engagement,27 using a quantitative systems pharmacology
approach.28 Another recent example is the label change
for nivolumab from 3 mg/kg every 2 weeks to 480 mg every
4 weeks, which was also based on a study conducted
in silico.29
BEYOND PK/PD MODELING: MECHANISTIC LEARNING FOR
THE DESIGN OF COMBINATORY CLINICAL TRIALS
Thus, there is a need for semi-mechanistic models that are
able to use the growing amount of quantitative information
coming from clinical studies, such as longitudinal data (eg,
tumor size, immune biomarkers, or circulating tumor DNA),
to create useful simulations of therapeutic regimens (Fig 1).
Of note, such mechanistic models have started to show
their utility in the design of clinical trials, although this has
been limited to settings other than immunotherapy thus
far.30 For instance, the MODEL1 trial (ClinicalTrials.gov
identifier: NCT02392845) of a combinatorial regimen in
breast cancer and the MetroVino trial (ClinicalTrials.gov
identifier: NCT02555007) in lung cancer were both clinical
studies entirely driven by mathematical models that identi-
fied in silico a complex regimen to be tested at bedside.31-33
In the MODEL1 study, neutrophil count monitoring allowed
the investigators to perform patient-centered dose individ-
ualization so as to limit the incidence of bone marrow
toxicity.31,32 Such model-informed design could be trans-
posed to preserve immune cells when cytotoxics are to be
further associated with IODs.
Other investigators have transposed biologic principles of
cancer eco-evolutionary dynamics into mathematical
models to understand and predict the onset of resistance to
anti-EGFR therapies in lung cancer.34 Using models of
polyclonal tumor growth, an alternative regimen consisting
of a combination of pulse dosing and daily low-dose
erlotinib was suggested.35 The strategy was further tested
in a clinical trial but did not outperform the standard
scheme.36 A likely explanation given by the authors was that
peak concentrations did not reach high enough levels in
patients in comparison with the in vivo studies. However,
interpatient PK variability was not modeled using, for ex-
ample, mixed-effects statistical techniques.37 Combining
advanced mathematical modeling with such methods
would probably be beneficial. Critically, it would also be
highly informative to analyze the data generated using the
initial model to close the mechanistic learning loop.
Using similar principles for tumor heterogeneity, others
have proposed the concept of adaptive therapy, suggesting
individuals be treated only upon disease progression.38 This
was further successfully translated at bedside in patients
with metastatic castration-resistant prostate cancer.39 Such
a strategy could help to personalize combinations of IODs
and aromatase inhibitors in the neoadjuvant treatment of
breast cancer.40
Despite their scarcity, these studies highlight how appli-
cation of mathematical modeling in clinical trials in on-
cology is now feasible and can rationalize study design.
These innovative methods are yet to be extended to IOD
combinations. Modeling immunotherapy has recently been
applied to gain insights on optimal modes for combinations
with RT.41-43 For instance, Kosinsky et al42 were able to
simulate multiple sequences of anti–PD-1 treatment in
combination with RT and validated their results using
preclinical data. They predicted that hyperfractionated RT
regimens had worse efficacy in shrinking tumor size than
single-dose regimens. Empirical confirmation or invalidation
of such predictions in a clinical setting would be crucial
to close the mechanistic learning loop. In another study,
a simple model calculating an immunologically effective dose
(IED) has been proposed for RT fractionation schemes,44 thus
suggesting that this kind of algorithm could be used as in silico
decision-making tools.
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The general modeling methodology that could be
undertaken—mechanistic learning—is a combination of
mechanistic modeling and statistical learning, either from
machine learning, mixed-effects learning,45 or survival
learning,46 for integration of the multimodal data arising from
clinical trials or routine management (Fig 1). As output, it
would provide informative simulations of the effect of various
doses and schedules to aid decisions in early clinical studies.
These would consist of predicted probabilities of graded
toxicities, tumor growth kinetics in response to treatment,
and survival outcomes. Of note, there is a major trend by
health regulatory agencies such as the US Food and Drug
Administration to call for incorporating extensive modeling
and simulation into clinical research.47 In this respect, and
regarding the current challenges with IODs,48 we believe that
mechanistic learning could be a valuable tool for decision
making when setting up combinatorial strategies.
CONCLUSION
After a first phase of enthusiasm, success stories with im-
munotherapy seem to have reached a glass ceiling because
many studies now fail to further stretch either response rates
or survival.49 Consequently, combining immune checkpoint
inhibitors with other treatments likely to boost tumor immunity
is a rising strategy in clinical oncology. However, current
designs are suboptimal with respect to the complexity of
finding the right dosing, scheduling, and sequencing of im-
mune checkpoint inhibitors. We advocate that mechanistic
learning could reduce the attrition rate of combinatorial
studies through innovative model-informed designs.
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La Timone, Assistance Publique–Hôpitaux de Marseille, Marseille,
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